Toxicity compare

Adverse-event rates side by side across products of the same class. Any-grade and grade 3 or higher, from the US prescribing information where read. Blank means not sourced, not zero. Trial populations differ, so compare with care.

138 of 983 adverse-event rows

				Trial / note
Neutropenia	Brentuximab vedotin ADC	91%	82%	ECHELON-1, A+AVD arm · source
Neutropenia	Sacituzumab govitecan ADC	78%	49%	ASCENT, Trodelvy arm, n=258 · source
Thrombocytopenia	Inotuzumab ozogamicin ADC	—	41%
Neutropenia	Trastuzumab rezetecan ADC	—	40%
Neutropenia	Polatuzumab vedotin ADC	—	28.3%
Neutropenia Febrile neutropenia	Inotuzumab ozogamicin ADC	—	27%
Neutropenia Febrile neutropenia	Brentuximab vedotin ADC	19%	19%	ECHELON-1, A+AVD arm · source
Neutropenia	Trastuzumab deruxtecan ADC	—	18%	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Rash / skin Rash	Enfortumab vedotin ADC	68%	15%	EV-302 with pembrolizumab, n=440 · source
Hyperglycaemia Hyperglycaemia (grade 3-4 glucose elevation)	Enfortumab vedotin ADC	—	14%	EV-302 with pembrolizumab, n=440 · source
Neutropenia Febrile neutropenia	Polatuzumab vedotin ADC	—	13.8%
Diarrhoea	Sacituzumab govitecan ADC	59%	11%	ASCENT, Trodelvy arm, n=258 · source
Peripheral neuropathy Peripheral sensory neuropathy	Brentuximab vedotin ADC	65%	10%	ECHELON-1, A+AVD arm · source
Anaemia	Sacituzumab govitecan ADC	94%	9%	ASCENT, Trodelvy arm, n=258 · source
Peripheral neuropathy	Enfortumab vedotin ADC	67%	8%	EV-302 with pembrolizumab, n=440 · source
Anaemia	Trastuzumab deruxtecan ADC	—	7%	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Nausea	Trastuzumab deruxtecan ADC	—	7%	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Stomatitis	Datopotamab deruxtecan ADC	59%	7%	TROPION-Breast01, n=360 · source
Fatigue	Enfortumab vedotin ADC	51%	6%	EV-302 with pembrolizumab, n=440 · source
Fatigue	Sacituzumab govitecan ADC	65%	6%	ASCENT, Trodelvy arm, n=258 · source
Fatigue	Trastuzumab deruxtecan ADC	—	6%	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Peripheral neuropathy	Tisotumab vedotin ADC	38%	6%	innovaTV 301, n=250 · source
Thrombocytopenia	Trastuzumab emtansine ADC	29%	6%	KATHERINE (adjuvant) · source
Diarrhoea	Enfortumab vedotin ADC	38%	4.5%	EV-302 with pembrolizumab, n=440 · source
Fatigue	Datopotamab deruxtecan ADC	44%	4.2%	TROPION-Breast01, n=360 · source
Weight decrease	Enfortumab vedotin ADC	33%	3.6%	EV-302 with pembrolizumab, n=440 · source
Corneal complications	Tisotumab vedotin ADC	—	3.2%	innovaTV 301, n=250 · source
Nausea	Sacituzumab govitecan ADC	57%	3.1%	ASCENT, Trodelvy arm, n=258 · source
Vomiting	Brentuximab vedotin ADC	33%	3%	ECHELON-1, A+AVD arm · source
Constipation	Brentuximab vedotin ADC	42%	2%	ECHELON-1, A+AVD arm · source
Nausea	Brentuximab vedotin ADC	40%	2%	ECHELON-1, A+AVD arm · source
Decreased appetite	Enfortumab vedotin ADC	33%	1.8%	EV-302 with pembrolizumab, n=440 · source
Decreased appetite	Sacituzumab govitecan ADC	28%	1.6%	ASCENT, Trodelvy arm, n=258 · source
Peripheral neuropathy	Polatuzumab vedotin ADC	52.9%	1.6%	POLARIX Pola-R-CHP arm
Vomiting	Sacituzumab govitecan ADC	33%	1.6%	ASCENT, Trodelvy arm, n=258 · source
Nausea	Datopotamab deruxtecan ADC	56%	1.4%	TROPION-Breast01, n=360 · source
Ocular Keratitis	Datopotamab deruxtecan ADC	24%	1.1%	TROPION-Breast01, n=360 · source
Pruritus	Enfortumab vedotin ADC	41%	1.1%	EV-302 with pembrolizumab, n=440 · source
Vomiting	Datopotamab deruxtecan ADC	24%	1.1%	TROPION-Breast01, n=360 · source
Ocular Dry eye	Datopotamab deruxtecan ADC	27%	0.8%	TROPION-Breast01, n=360 · source
Alopecia	Enfortumab vedotin ADC	35%	0.5%	EV-302 with pembrolizumab, n=440 · source
Constipation	Sacituzumab govitecan ADC	37%	0.4%	ASCENT, Trodelvy arm, n=258 · source
Rash / skin Rash	Sacituzumab govitecan ADC	12%	0.4%	ASCENT, Trodelvy arm, n=258 · source
Constipation	Datopotamab deruxtecan ADC	34%	0.3%	TROPION-Breast01, n=360 · source
Alopecia	Datopotamab deruxtecan ADC	38%	0%	TROPION-Breast01, n=360 · source
Alopecia	Sacituzumab govitecan ADC	47%	0%	ASCENT, Trodelvy arm, n=258 · source
Ocular Dry eye	Enfortumab vedotin ADC	24%	0%	EV-302 with pembrolizumab, n=440 · source
Abdominal pain	Mirvetuximab soravtansine ADC	34%	—	MIRASOL; all-grade rates · source
Alopecia	Disitamab vedotin ADC	—	—
Alopecia	Sacituzumab tirumotecan ADC	—	—
Alopecia	Tisotumab vedotin ADC	24%	—	innovaTV 301, n=250 · source
Alopecia	Trastuzumab deruxtecan ADC	—	—	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Anaemia	Ifinatamab deruxtecan ADC	—	—
Anaemia	Loncastuximab tesirine ADC	—	—
Anaemia	Raludotatug deruxtecan ADC	—	—
Anaemia	Sacituzumab tirumotecan ADC	—	—
Constipation	Trastuzumab deruxtecan ADC	—	—	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Decreased appetite	Ifinatamab deruxtecan ADC	—	—
Decreased appetite	Sonesitatug vedotin ADC	—	—
Decreased appetite	Telisotuzumab vedotin ADC	—	—
Decreased appetite	Tisotumab vedotin ADC	24%	—	innovaTV 301, n=250 · source
Decreased appetite	Trastuzumab deruxtecan ADC	—	—	DESTINY-Breast03/04; all-grade rates ≥20% per label · source
Diarrhoea	Mirvetuximab soravtansine ADC	29%	—	MIRASOL; all-grade rates · source
Diarrhoea	Polatuzumab vedotin ADC	30.8%	—
Epistaxis	Tisotumab vedotin ADC	26%	—	innovaTV 301, n=250 · source
Fatigue	Loncastuximab tesirine ADC	—	—
Fatigue	Mirvetuximab soravtansine ADC	47%	—	MIRASOL; all-grade rates · source
Fatigue	Patritumab deruxtecan ADC	—	—
Fatigue	Puxitatug samrotecan ADC	—	—
Fatigue	Raludotatug deruxtecan ADC	—	—
Fatigue	Telisotuzumab vedotin ADC	—	—
Fatigue	Tisotumab vedotin ADC	28%	—	innovaTV 301, n=250 · source
Fatigue	Trastuzumab emtansine ADC	50%	—	KATHERINE (adjuvant) · source
Fatigue	Zilovertamab vedotin ADC	—	—
Haemorrhage	Gemtuzumab ozogamicin ADC	—	—
Haemorrhage	Tisotumab vedotin ADC	21%	—	innovaTV 301, n=250 · source
Haemorrhage	Trastuzumab emtansine ADC	29%	—	KATHERINE (adjuvant) · source
Headache	Trastuzumab emtansine ADC	28%	—	KATHERINE (adjuvant) · source
Hepatotoxicity AST/ALT increased	Disitamab vedotin ADC	—	—
Hepatotoxicity Hepatotoxicity including veno-occlusive disease	Gemtuzumab ozogamicin ADC	—	—
Hepatotoxicity Hepatic veno-occlusive disease	Inotuzumab ozogamicin ADC	14%	—	Boxed warning; 22% of those who went on to transplant in INO-VATE · source
Hepatotoxicity Transaminase elevation	Inotuzumab ozogamicin ADC	27%	—
Hepatotoxicity AST increased	Mirvetuximab soravtansine ADC	57%	—	MIRASOL; all-grade rates · source
Hepatotoxicity ALT increased	Mirvetuximab soravtansine ADC	38%	—	MIRASOL; all-grade rates · source
Hepatotoxicity Transaminases increased	Trastuzumab emtansine ADC	32%	—	KATHERINE (adjuvant) · source
ILD / pneumonitis ILD/pneumonitis	Ifinatamab deruxtecan ADC	—	—
ILD / pneumonitis ILD/pneumonitis	Patritumab deruxtecan ADC	—	—
ILD / pneumonitis Interstitial lung disease / pneumonitis	Trastuzumab deruxtecan ADC	12%	—	0.9% fatal; pooled breast studies at 5.4 mg/kg · source
ILD / pneumonitis Interstitial lung disease	Trastuzumab rezetecan ADC	4%	—
Increased GGT	Loncastuximab tesirine ADC	—	—
Infections	Belantamab mafodotin ADC	—	—
Infections Infection	Gemtuzumab ozogamicin ADC	—	—
Infusion reactions	Gemtuzumab ozogamicin ADC	—	—
Left ventricular dysfunction	Trastuzumab emtansine ADC	3%	—	KATHERINE (adjuvant) · source
Musculoskeletal pain	Trastuzumab emtansine ADC	30%	—	KATHERINE (adjuvant) · source
Nausea	Ifinatamab deruxtecan ADC	—	—
Nausea	Mirvetuximab soravtansine ADC	27%	—	MIRASOL; all-grade rates · source
Nausea	Patritumab deruxtecan ADC	—	—
Nausea	Puxitatug samrotecan ADC	—	—
Nausea	Raludotatug deruxtecan ADC	—	—
Nausea	Sacituzumab tirumotecan ADC	—	—
Nausea	Sonesitatug vedotin ADC	—	—
Nausea	Telisotuzumab vedotin ADC	—	—
Nausea	Tisotumab vedotin ADC	33%	—	innovaTV 301, n=250 · source
Nausea	Trastuzumab emtansine ADC	42%	—	KATHERINE (adjuvant) · source
Nausea	Trastuzumab rezetecan ADC	60%	—
Neutropenia	Disitamab vedotin ADC	—	—
Neutropenia	Ifinatamab deruxtecan ADC	—	—
Neutropenia	Loncastuximab tesirine ADC	—	—
Neutropenia	Patritumab deruxtecan ADC	—	—
Neutropenia	Puxitatug samrotecan ADC	—	—
Neutropenia	Raludotatug deruxtecan ADC	—	—
Neutropenia	Sacituzumab tirumotecan ADC	—	—	Most common grade ≥3 event in OptiTROP-Breast01; rates per publication
Neutropenia	Sonesitatug vedotin ADC	—	—
Neutropenia	Zilovertamab vedotin ADC	—	—
Ocular Keratopathy	Belantamab mafodotin ADC	—	—	Ocular events in most patients; boxed warning
Ocular Blurred vision	Belantamab mafodotin ADC	—	—
Ocular Dry eye	Belantamab mafodotin ADC	—	—
Ocular Blurred vision	Mirvetuximab soravtansine ADC	45%	—	MIRASOL; all-grade rates · source
Ocular Keratopathy	Mirvetuximab soravtansine ADC	37%	—	MIRASOL; all-grade rates · source
Ocular Dry eye	Mirvetuximab soravtansine ADC	29%	—	MIRASOL; all-grade rates · source
Ocular Conjunctival disorders	Tisotumab vedotin ADC	37%	—	innovaTV 301, n=250 · source
Ocular Dry eye	Tisotumab vedotin ADC	21%	—	innovaTV 301, n=250 · source
Oedema and effusions	Loncastuximab tesirine ADC	—	—
Peripheral neuropathy	Disitamab vedotin ADC	—	—
Peripheral neuropathy	Mirvetuximab soravtansine ADC	37%	—	MIRASOL; all-grade rates · source
Peripheral neuropathy	Telisotuzumab vedotin ADC	—	—
Peripheral neuropathy	Trastuzumab emtansine ADC	28%	—	KATHERINE (adjuvant) · source
Peripheral neuropathy	Zilovertamab vedotin ADC	—	—
Peripheral oedema	Telisotuzumab vedotin ADC	—	—
Rash / skin Photosensitivity/rash	Loncastuximab tesirine ADC	—	—
Stomatitis	Sacituzumab tirumotecan ADC	—	—
Thrombocytopenia	Belantamab mafodotin ADC	—	—
Thrombocytopenia	Gemtuzumab ozogamicin ADC	—	—
Thrombocytopenia	Loncastuximab tesirine ADC	—	—
Thrombocytopenia	Patritumab deruxtecan ADC	—	—
Vomiting	Sonesitatug vedotin ADC	—	—
Vomiting	Trastuzumab deruxtecan ADC	—	—	DESTINY-Breast03/04; all-grade rates ≥20% per label · source